| Autor: |
Youssouf Diarra, Oumar Koné, Lansana Sangaré, Lassina Doumbia, Dade Bouye Ben Haidara, Mouctar Diallo, Ababacar Maiga, Hamadoun A. Sango, Halidou Sidibé, Jules Mihigo, Douglas Nace, Dragan Ljolje, Eldin Talundzic, Venkatachalam Udhayakumar, Erin Eckert, Celia J. Woodfill, Leah F. Moriarty, Pharath Lim, Donald J. Krogstad, Eric S. Halsey, Naomi W. Lucchi, Ousmane A. Koita |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Malaria Journal, Vol 20, Iss 1, Pp 1-13 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1475-2875 |
| DOI: |
10.1186/s12936-021-03760-9 |
| Popis: |
Abstract Background The current first-line treatments for uncomplicated malaria recommended by the National Malaria Control Programme in Mali are artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ). From 2015 to 2016, an in vivo study was carried out to assess the clinical and parasitological responses to AL and ASAQ in Sélingué, Mali. Methods Children between 6 and 59 months of age with uncomplicated Plasmodium falciparum infection and 2000–200,000 asexual parasites/μL of blood were enrolled, randomly assigned to either AL or ASAQ, and followed up for 42 days. Uncorrected and PCR-corrected efficacy results at days 28 and 42. were calculated. Known markers of resistance in the Pfk13, Pfmdr1, and Pfcrt genes were assessed using Sanger sequencing. Results A total of 449 patients were enrolled: 225 in the AL group and 224 in the ASAQ group. Uncorrected efficacy at day 28 was 83.4% (95% CI 78.5–88.4%) in the AL arm and 93.1% (95% CI 89.7–96.5%) in the ASAQ arm. The per protocol PCR-corrected efficacy at day 28 was 91.0% (86.0–95.9%) in the AL arm and 97.1% (93.6–100%) in the ASAQ arm. ASAQ was significantly (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
